Renal manifestations of systemic sclerosis - Clinical features and outcome assessment

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Denton, C P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Biopsy; Endothelin 1; Incidence; Renal crisis; Scleroderma; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR; NITRATE; PENICILLAMINE; PLACEBO; PROSTACYCLIN; SITAXSENTAN; VASODILATOR AGENT;

ALLOGRAFT; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSIS; DRUG DOSE INCREASE; DRUG EFFICACY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; RENAL REPLACEMENT THERAPY; SCLERODERMA; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 69949182476     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken307     Document Type: Conference Paper

References (18)

1. Penn H, Howie AJ, Kingdon EJ et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 2007;100:485-94.
2. Teixeira L, Mouthon L, Mahr A et al. Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients. Ann Rheum Dis 2008;67:110-6.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
4. Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: A report of three cases. Br J Rheumatol 1994;33:90-2.
5. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
6. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
7. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R. Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 1997;15:135-41.
8. Scorza R, Rivolta R, Mascagni B et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997;24:1944-8.
9. Gibney EM, Parikh CR, Jani A, Fischer MJ, Collier D, Wiseman AC. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004;4:2027-31.
10. Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma - a different kind of renal crisis. J Rheumatol 2006;33:1886-8.
11. Kingdon EJ, Knight CJ, Dustan K et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 2003;42:26-33.
12. Denton CP, Bickerstaff MC, Shiwen X et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
13. Stratton RJ, Coghlan JG, Pearson JD et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. Q J Med 1998;91:561-6.
14. Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
15. Kobayashi H, Nishimaki T, Kaise S et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999;18:425-7.
16. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999;117:395-402.
17. Fonseca C, Renzoni E, Sestini P et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 2006;54:3034-42.
18. Wollheim FA. ACE inhibitors could prevent long-term damage in systemic sclerosis patients experiencing scleroderma renal crisis. Clin Exp Rheumatol 2002;20:613-4.